Last reviewed · How we verify
NCT05995015
4SCAR19U T Cells Targeting B Cell Malignancies
Phase 1 trial testing Universal CD19-specific CAR gene-engineered T cells in B Cell Malignancies in 30 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | Shenzhen Geno-Immune Medical Institute |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 31 October 2023 |
| Primary completion | 30 September 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Universal CD19-specific CAR gene-engineered T cells — full drug profile →
Conditions studied
- B Cell Malignancies — all drugs for B Cell Malignancies →
Sponsor
Shenzhen Geno-Immune Medical Institute
Who can join
Adults 6 Months to 75, any sex, with B Cell Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05995015
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B Cell Malignancies
Currently open trials in the same condition.
- NCT07135466 — A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expres · Phase 1, PHASE2 · recruiting
- NCT06576102 — Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients · active not recruiting
- NCT06375161 — Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. · EARLY_PHASE1 · recruiting
- NCT05436496 — CD19/70 Bi-specific CAR-T Cell Therapy · Phase 1, PHASE2 · recruiting
- NCT05436509 — CD19/79b Bi-specific CAR-T Cell Therapy · Phase 1, PHASE2 · recruiting
Other Shenzhen Geno-Immune Medical Institute trials
Trials by the same sponsor.
- NCT07501156 — H3K27M-specific Immune Effector Cells Targeting DMG/DIPG · Phase 1, PHASE2 · recruiting
- NCT07495956 — cfMSC Therapy for Diabetes · Phase 1, PHASE2 · recruiting
- NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
- NCT07180927 — DLL3 CAR-T Therapy Targeting Brain Tumors · Phase 1, PHASE2 · recruiting
- NCT07193966 — NG2 and DLL3 CAR-T Cells Targeting Melanoma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05995015 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Geno-Immune Medical Institute
- Last refreshed: 12 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05995015.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing